Smith & Nephew’s (SN) Buy Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reaffirmed their buy rating on shares of Smith & Nephew (LON:SN) in a research report sent to investors on Friday morning,Digital Look reports. They currently have a GBX 1,500 price objective on the stock.

Several other equities research analysts also recently issued reports on the company. Citigroup downgraded Smith & Nephew to a “buy” rating in a report on Friday, July 10th. Shore Capital Group reiterated a “buy” rating and set a GBX 1,000 target price on shares of Smith & Nephew in a research note on Tuesday, July 21st. Berenberg Bank decreased their price target on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating for the company in a research report on Friday, August 14th. JPMorgan Chase & Co. dropped their price target on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 1,400 price target on shares of Smith & Nephew in a report on Thursday, July 30th. Three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of GBX 1,310.

Smith & Nephew Stock Performance

LON:SN opened at GBX 1,064 on Friday. The firm has a market capitalization of £11.66 billion, a PE ratio of 38.31, a price-to-earnings-growth ratio of 0.46 and a beta of 0.69. The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14. The stock has a 50 day simple moving average of GBX 1,116.26 and a 200-day simple moving average of GBX 1,167.89.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.